RCEL

AVITA Medical, Inc.

$17.65

3.10%
SectorHealthcareIndustryMedical DevicesCountryUnited States

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

Source: Yahoo Finance
AI summary

Price & performance

1M+20.5%
3M+231.8%
YTD+341.8%
1Y+305.6%
52-week range—
Beta1.54
Full chart and returns against a benchmark

Q-Score

58/ 100

Quality against peers; 50 is the peer median.

Growth73
Risk46
Performance65
Valuation51
Profitability51
Leverage41
Sentiment87
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$70.9M+10.9%
Net income-$48.6M
Net margin-68.5%+28.2 pts
Historical fundamentals

Red flags in filings

1active red flag
Going-concern doubtFeb 12, 2026
Filings, findings and the timeline

Revenue exposure

4%of revenue from outside the US
United States96%
Japan3%
United Kingdom1%
Largest customer10%
Regions, segments, customers and suppliers

Valuation

RCELIndustryP/E—29.61P/S6.613.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate$-0.29
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate